REN

NCT01721577 — Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas

Status: TERMINATED · clinicaltrials.gov

NCT02669173 — Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

Status: COMPLETED · clinicaltrials.gov

NCT05053880 — A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Status: UNKNOWN · clinicaltrials.gov

NCT03660761 — Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Status: COMPLETED · clinicaltrials.gov

NCT00979862 — Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Status: COMPLETED · clinicaltrials.gov

NCT00761280 — Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Status: TERMINATED · clinicaltrials.gov

NCT00293423 — GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma

Status: COMPLETED · clinicaltrials.gov

NCT00813943 — Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status

Status: COMPLETED · clinicaltrials.gov

NCT02223052 — Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Status: COMPLETED · clinicaltrials.gov

NCT06831526 — Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Status: RECRUITING · clinicaltrials.gov

NCT04051606 — Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

Status: COMPLETED · clinicaltrials.gov

NCT01582269 — A Study in Recurrent Glioblastoma (GB)

Status: COMPLETED · clinicaltrials.gov

NCT05909618 — Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

Status: RECRUITING · clinicaltrials.gov

NCT00797940 — Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)

Status: WITHDRAWN · clinicaltrials.gov

NCT01124240 — Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene

Status: UNKNOWN · clinicaltrials.gov

NCT03034135 — Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Status: COMPLETED · clinicaltrials.gov

NCT03115333 — DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov

NCT00006358 — Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor

Status: COMPLETED · clinicaltrials.gov

NCT01631552 — Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Status: COMPLETED · clinicaltrials.gov

NCT00387933 — Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Status: COMPLETED · clinicaltrials.gov

NCT01849146 — Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

Status: COMPLETED · clinicaltrials.gov

NCT02698280 — Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma

Status: COMPLETED · clinicaltrials.gov

NCT00104091 — Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

Status: COMPLETED · clinicaltrials.gov

NCT00704080 — A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Status: COMPLETED · clinicaltrials.gov

NCT03107780 — Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Status: TERMINATED · clinicaltrials.gov

NCT03626896 — Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients

Status: COMPLETED · clinicaltrials.gov

NCT03033524 — Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma

Status: COMPLETED · clinicaltrials.gov

NCT00433381 — Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Status: COMPLETED · clinicaltrials.gov

NCT02433392 — Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme.

Status: TERMINATED · clinicaltrials.gov

NCT06672575 — A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

Status: RECRUITING · clinicaltrials.gov

NCT00071539 — Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

Status: COMPLETED · clinicaltrials.gov

NCT01011231 — Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma

Status: TERMINATED · clinicaltrials.gov

NCT03705351 — Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

Status: TERMINATED · clinicaltrials.gov

NCT01499251 — Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

Status: TERMINATED · clinicaltrials.gov

NCT00584883 — A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

Status: COMPLETED · clinicaltrials.gov

NCT01985256 — Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor

Status: COMPLETED · clinicaltrials.gov

NCT06072586 — A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

Status: RECRUITING · clinicaltrials.gov

NCT00509431 — Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

Status: COMPLETED · clinicaltrials.gov

NCT04671459 — TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine

Status: UNKNOWN · clinicaltrials.gov

NCT01865162 — Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study

Status: COMPLETED · clinicaltrials.gov

NCT02661282 — Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma

Status: COMPLETED · clinicaltrials.gov

NCT01925573 — Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)

Status: TERMINATED · clinicaltrials.gov

NCT03596086 — HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

Status: RECRUITING · clinicaltrials.gov

NCT00006246 — Busulfan in Treating Children and Adolescents With Refractory CNS Cancer

Status: COMPLETED · clinicaltrials.gov

NCT00979173 — Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma

Status: COMPLETED · clinicaltrials.gov

NCT02800486 — Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Status: RECRUITING · clinicaltrials.gov

NCT04221503 — Niraparib/TTFields in GBM

Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov

NCT03463265 — Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

Status: COMPLETED · clinicaltrials.gov

NCT00727506 — BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma

Status: COMPLETED · clinicaltrials.gov

NCT02394665 — Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma

Status: TERMINATED · clinicaltrials.gov

NCT01062399 — Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Status: COMPLETED · clinicaltrials.gov

NCT04547621 — HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM

Status: UNKNOWN · clinicaltrials.gov

NCT07138001 — Phase 2 Clinical Trial of KH617

Status: NOT_YET_RECRUITING · clinicaltrials.gov

NCT00752323 — Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma

Status: COMPLETED · clinicaltrials.gov

NCT02815410 — Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients

Status: UNKNOWN · clinicaltrials.gov

NCT04863950 — Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

Status: RECRUITING · clinicaltrials.gov

NCT04600817 — A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

Status: UNKNOWN · clinicaltrials.gov

NCT00780819 — Borderzone Sampling

Status: COMPLETED · clinicaltrials.gov

NCT05765812 — A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Status: RECRUITING · clinicaltrials.gov

NCT00036894 — CC-5013 in Treating Patients With Recurrent Glioma

Status: COMPLETED · clinicaltrials.gov

NCT02678975 — Disulfiram in Recurrent Glioblastoma

Status: COMPLETED · clinicaltrials.gov

NCT04547855 — Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen

Status: UNKNOWN · clinicaltrials.gov

NCT05708352 — A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment

Status: RECRUITING · clinicaltrials.gov

NCT04656535 — AB154 Combined With AB122 for Recurrent Glioblastoma

Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov

NCT06558214 — OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial

Status: RECRUITING · clinicaltrials.gov

NCT04440358 — Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

Status: COMPLETED · clinicaltrials.gov

NCT01478178 — Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma

Status: COMPLETED · clinicaltrials.gov

NCT07485049 — BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors

Status: RECRUITING · clinicaltrials.gov

NCT04143425 — Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma

Status: COMPLETED · clinicaltrials.gov

NCT01989884 — An Efficacy Study Of Ortataxel In Recurrent Glioblastoma

Status: COMPLETED · clinicaltrials.gov

NCT00800917 — A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme

Status: COMPLETED · clinicaltrials.gov

NCT03687034 — A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma

Status: UNKNOWN · clinicaltrials.gov

NCT03618667 — GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

Status: COMPLETED · clinicaltrials.gov

NCT04854044 — ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma

Status: WITHDRAWN · clinicaltrials.gov

NCT07521657 — Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma

Status: NOT_YET_RECRUITING · clinicaltrials.gov

NCT02658981 — Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Status: COMPLETED · clinicaltrials.gov

NCT04590664 — Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

Status: RECRUITING · clinicaltrials.gov

NCT04222309 — Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)

Status: SUSPENDED · clinicaltrials.gov

NCT02253212 — Safety of BBB Opening With the SonoCloud

Status: COMPLETED · clinicaltrials.gov

NCT04846257 — Specific Preoperative Dynamic Contrast-enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of the Glioblastoma Tissue and Predict Recurrence

Status: COMPLETED · clinicaltrials.gov

NCT06177964 — Lerapolturev (PVSRIPO) in GBM

Status: RECRUITING · clinicaltrials.gov

NCT05241392 — Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma

Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov

NCT00609999 — Ph I Dasatinib + Erlotinib in Recurrent MG

Status: COMPLETED · clinicaltrials.gov

NCT00562419 — CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

Status: UNKNOWN · clinicaltrials.gov

NCT03275558 — Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Status: WITHDRAWN · clinicaltrials.gov

NCT03466450 — Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma

Status: COMPLETED · clinicaltrials.gov

NCT04541225 — Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

Status: TERMINATED · clinicaltrials.gov

NCT00823797 — Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

Status: COMPLETED · clinicaltrials.gov

NCT02717962 — Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting

Status: COMPLETED · clinicaltrials.gov

NCT01782976 — Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Status: WITHDRAWN · clinicaltrials.gov

NCT00004024 — Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma

Status: COMPLETED · clinicaltrials.gov

NCT00895180 — Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Status: COMPLETED · clinicaltrials.gov

NCT05879120 — Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Status: WITHDRAWN · clinicaltrials.gov

NCT00939991 — Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas

Status: COMPLETED · clinicaltrials.gov

NCT04991870 — Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

Status: RECRUITING · clinicaltrials.gov

NCT00305656 — AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Status: COMPLETED · clinicaltrials.gov

NCT02444546 — Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

Status: COMPLETED · clinicaltrials.gov

NCT06359379 — Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Status: TERMINATED · clinicaltrials.gov

NCT04047303 — CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Status: TERMINATED · clinicaltrials.gov

NCT04908176 — A Drug-drug Interaction Study of Avapritinib and Midazolam

Status: COMPLETED · clinicaltrials.gov

NCT00095940 — Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors

Status: COMPLETED · clinicaltrials.gov

NCT03152318 — A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov

NCT04536649 — Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma.

Status: UNKNOWN · clinicaltrials.gov

NCT01870726 — Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

Status: TERMINATED · clinicaltrials.gov

NCT02575027 — Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme

Status: COMPLETED · clinicaltrials.gov

NCT01342757 — Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma

Status: COMPLETED · clinicaltrials.gov

NCT03970447 — A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Status: RECRUITING · clinicaltrials.gov

NCT02974621 — Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov

NCT06501911 — A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma

Status: WITHDRAWN · clinicaltrials.gov

NCT05557292 — RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

Status: TERMINATED · clinicaltrials.gov

NCT06499831 — 18F-FET-PET/MRI vs Standard MRI Alone for Stereotactic RadioTherapy Planning for High Grade Brain Gliomas

Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov

NCT06264388 — DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Status: RECRUITING · clinicaltrials.gov

NCT00499473 — Sunitinib in Treating Patients With Recurrent Malignant Gliomas

Status: COMPLETED · clinicaltrials.gov